<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="128574">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01428336</url>
  </required_header>
  <id_info>
    <org_study_id>1945</org_study_id>
    <nct_id>NCT01428336</nct_id>
  </id_info>
  <brief_title>Value of 25 mcg Cortrosyn Stimulation Test</brief_title>
  <acronym>25CST</acronym>
  <official_title>The Value of 25 mcg Cortrosyn Stimulation Test to Assess Adult HPA Axis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The diagnosis of secondary AI is vital to prevent catastrophic events in patients. An
      optimal test should have a very low margin of error with high sensitivity and specificity,
      be easy and safe to administer, and have distinct cut off values. Both 1 ug and 250 ug doses
      have their limitations. Based on our experience over the past six years, we hypothesize that
      25 ug ACTH stimulation test may eliminate some of the shortcomings of the LDST (1 ug) and
      SDST (250 ug). This is supported by our preliminary data and the study by Oelkers et al,
      which looked at ACTH levels following various doses of cortrosyn injections.

      Therefore we propose a head to head comparison of 25 ug, 250 ug and 1 ug dose using ITT as
      gold standard.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak cortisol values</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACTH level</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Adrenal Insufficiency</condition>
  <arm_group>
    <arm_group_label>1ug cortrosyn dose stimulation test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo an ACTH stimulation test using a dose of 1 ug cotrosyn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>250 ug cortrosyn dose stimulation test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo an ACTH stimulation test using 250 ug cortrosyn dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 ug cortrosyn stimulation test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo an ACTH stimulation test using a 25 ug cortosyn dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin tolerance test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo an Insulin Tolerance Test</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ACTH stimulation test</intervention_name>
    <description>1 ug cortrosyn dose</description>
    <arm_group_label>1ug cortrosyn dose stimulation test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>250 ug ACTH stimulation test</intervention_name>
    <description>ACTH stimulation test will be done using 250 ug cortrosyn dose</description>
    <arm_group_label>250 ug cortrosyn dose stimulation test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>25 ug Cortrosyn stimulation test</intervention_name>
    <description>ACTH stimulation test using a 25 ug cortrosyn dose</description>
    <arm_group_label>25 ug cortrosyn stimulation test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Insulin tolerance test</intervention_name>
    <description>subjects will undergo an insulin tolerance test</description>
    <arm_group_label>Insulin tolerance test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>1 ug cortrosyn test</intervention_name>
    <description>Subjects will undergo an ACTH test using a 1 ug dose cortrosyn</description>
    <arm_group_label>1ug cortrosyn dose stimulation test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hypothalamic-pituitary-adrenal disorders

        Exclusion Criteria:

          -  under 18 or older than 65 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cleveland Clinic Department of Endocrinology</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 4, 2015</lastchanged_date>
  <firstreceived_date>September 1, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
    <mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
    <mesh_term>Cosyntropin</mesh_term>
    <mesh_term>beta-Endorphin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
